LipUm: Funding, Investors & Team (Sep 2026)
Lipum aims to eliminate or alleviate painful symptoms for millions of patients suffering from chronic inflammatory diseases. Lipum has a biological anti-inflammatory drug candidate developed against Rheumatoid Arthritis (RA) – an autoimmune disease characterized by chronic inflammation of the joints. It often causes disability and lowers the quality of life for millions. Lipum also addresses the treatment of Juvenile Idiopathic Arthritis (JIA) that is a rare disease affecting children. A novel biological drug for this disease may be considered for an orphan drug designation. Treatment of other chronic inflammatory conditions is also explored. Related diseases are such as Crohn’s disease, ulcerative colitis, ankylosing spondylitis, and psoriatic arthritis. Lipum's biological anti-inflammatory drug candidate provides a novel mechanism of action. Therefore, it is assumed to have less adverse effects than current treatments in use.
LipUm has raised $12.8M across 3 funding rounds on record, the most recent an undisclosed round of $9.3M announced in Mar 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
LipUm Company Profile and Key Stats
Latest funding round on record: Mar 2026.
LipUm Funding Rounds
1 of 3 rounds was announced without a disclosed amount and is excluded from the total.
LipUm raised $3.5M in a Post-IPO Equity announced in Sep 2022.
2.3 years later, an undisclosed round was announced in Dec 2024 with no disclosed amount.
1.3 years later, an undisclosed round of $9.3M was announced in Mar 2026.
LipUm Founders and Leadership Team
Contact details for the LipUm team: 1 of 3 have an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →LipUm Funding Compared to Other Biotechnology Startups
LipUm's latest round of $9.3M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like LipUm in Biotechnology and Umeå
Companies Similar to LipUm
Pixelgen Technologies, established in Sweden in 2020, focuses on the advancement of biomedical research and…
Oblique Therapeutics is developing a new type of antibody-based medication for chronic pain and metastatic…
Emulsi Biotech is a biotechnology company that develops lipid technology to deliver biologic drugs orally.
Our vision is to develop and bring to the market safe and effective treatments for women specific diseases…
OncoZenge is a Swedish pharmaceutical company. It develops better products for the supportive care of cancer…
Elicera Therapeutics is a clinical stage immuno-oncology company developing cell and gene therapies for…
Alligator Bioscience is an innovative research based biotech company focused on developing novel drugs for…
Moleculent is dedicated to creating tech-based products that utilize fresh knowledge about the molecular…
Bio-Works was established in 2006 and specializes in creating, producing, and distributing cutting-edge…
Verigraft AB is a biotech company that creates personalized tissue-engineered transplants for use in…
ArgusEye is a biotech firm that offers sensor solutions for instant identification of biological systems and…
Cubase Bio is a biotechnology business that focuses on spatial biology tools. It creates solutions for 3D…
LipUm Funding FAQs
What does LipUm do?
Lipum aims to eliminate or alleviate painful symptoms for millions of patients suffering from chronic inflammatory diseases. Lipum has a biological anti-inflammatory drug candidate developed against Rheumatoid Arthritis (RA) – an autoimmune disease characterized by chronic inflammation of the joints. It often causes disability and lowers the quality of life for millions. Lipum also addresses the treatment of Juvenile Idiopathic Arthritis (JIA) that is a rare disease affecting children. A novel biological drug for this disease may be considered for an orphan drug designation. Treatment of other chronic inflammatory conditions is also explored. Related diseases are such as Crohn’s disease, ulcerative colitis, ankylosing spondylitis, and psoriatic arthritis. Lipum's biological anti-inflammatory drug candidate provides a novel mechanism of action. Therefore, it is assumed to have less adverse effects than current treatments in use.
How much funding has LipUm raised?
LipUm has raised $12.8M across 3 rounds on record. The most recent is an undisclosed round of $9.3M announced in Mar 2026.
When did LipUm last raise funding?
LipUm's most recent funding round on record is an undisclosed round of $9.3M, announced in Mar 2026.
Who founded LipUm?
FundedIQ lists Lennart Lundberg (Founder), Ola Sandborgh Ceo Lipum Ab (Founder), Olle Hernell (Founder) at LipUm.
Where is LipUm headquartered?
LipUm is based in Umeå, Vasterbottens Lan, Sweden.
How many employees does LipUm have?
LipUm is in the 1-10 employee band.
How does LipUm's funding compare to other Biotechnology startups?
LipUm's latest round of $9.3M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's LipUm Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for LipUm is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.